M. Schreuer

发表

Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?

B. Neyns, L. Brochez, N. van Geel, 2014, The British journal of dermatology.

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

B. Neyns, B. Bravenboer, B. Velkeniers, 2016, The Journal of clinical endocrinology and metabolism.

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

C. Bachert, B. Neyns, O. Krysko, 2015, Journal of Translational Medicine.

Incidental radiological finding of a renal tumour leading to the diagnosis of Birt-Hogg-Dube syndrome.

K. Verstraete, M. Lemmerling, M. Schreuer, 2011, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie.

Systemic immune changes associated with adjuvant interferon-&agr;2b-therapy in stage III melanoma patients: failure at the effector phase?

B. Neyns, L. Brochez, D. Allorge, 2015, Melanoma research.

Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)

E. Rozeman, C. Blank, H. Schmidt, 2016 .

3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases

B. Neyns, C. Heirman, K. Thielemans, 2015 .

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy

B. Neyns, V. del Marmol, H. El Housni, 2018, Melanoma research.

Effect of 5‐Bromodeoxyuridine on Differentiation

M. Schreuer, G. Czihak, 1978 .

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Bart Neyns, B. Neyns, Simon Planken, 2017, The Lancet. Oncology.

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

B. Neyns, P. Janssens, A. Hoorens, 2015, Melanoma research.

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure

B. Neyns, V. del Marmol, S. Wilgenhof, 2015, Melanoma research.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

B. Neyns, P. Coulie, V. del Marmol, 2016, Journal of Translational Medicine.

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

B. Neyns, R. Buyl, S. Wilgenhof, 2016, Journal of Translational Medicine.

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma

B. Neyns, S. Wilgenhof, G. Meersseman, 2016, Melanoma research.

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

C. Bachert, B. Neyns, O. Krysko, 2015, Journal of Translational Medicine.

Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma

C. Bachert, B. Neyns, O. Krysko, 2015, Oncoimmunology.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

S. Rorive, B. Neyns, V. del Marmol, 2015, Melanoma research.